Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), has radically altered daily life. Effective antiviral …

Abstract Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia with an unusual
outbreak in Wuhan, China, which is caused by severe acute respiratory syndrome …

Favipiravir and Molnupiravir, orally available antivirals, have been reported to exert antiviral
activity against SARS-CoV2. In recent days preliminary efficacy data have been reported in …

Αbstract Remdesivir (GS-5734), a drug initially developed to treat hepatitis C and Ebola
virus disease, was the first approved treatment for severe coronavirus disease 2019 (COVID …

The global pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2
or 2019-nCoV) has prompted multiple clinical trials to jumpstart search for anti-SARS-CoV-2 …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …

An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
was first reported in Wuhan, China in December 2019. An extremely high potential for …

Rapid changes in the viral genome allow viruses to evade threats posed by the host immune
response or antiviral drugs, and can lead to viral persistence in the host cells. RNA …

Coronaviruses are a large group of viruses known to cause illnesses that vary between the
common cold and more severe diseases to include severe acute respiratory syndrome …

The novel coronavirus, later identified as SARS-CoV-2, originating from Wuhan in China in
November 2019, quickly spread around the world becoming a pandemic. Despite the …